Management of leukopenia in kidney and pancreas transplant recipients

Clinical Transplantation

Volumn 22, Issue 6, 2008, Pages 822-828

  Hartmann, Erica L ^a   Gatesman, Mandy ^b   Roskopf Somerville, Julie ^c   Stratta, Robert ^d   Farney, Alan ^d   Sundberg, Aimee ^e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c Mountain View Pharmacy   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Kidney transplant; Leukopenia; Neutropenia; Pancreas transplant

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY PANCREAS TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYCOSIS; NEUTROPENIA; NEUTROPHIL COUNT; PANCREAS DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; FEMALE; GANCICLOVIR; GRAFT REJECTION; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 56349133216     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00893.x     Document Type: Article

References (25)

1. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002: 34: 730.
2. Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999: 67: 1011.
3. Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y. Induction therapy by anti-lymphocyte globulin (rabbit) in renal transplantation: A 1-yr follow-up of safety and efficacy. Clin Transplant 2003: 17: 539.
4. Walker JK, Scholz LM, Scheetz MH et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007: 83: 874.
5. Keown P, Hayry P, Mathew T et al. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996: 61: 1029.
6. Paya C, Humar A, Dominguez E et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004: 4: 611.
7. Royer B, Zanetta G, Berard M et al. A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil. Clin Transplant 2003: 17: 158.
8. Rerolle JP, Szelag JC, Le Meur Y. Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients. Nephrol Dial Transplant 2007: 22: 671.
9. Squifflet JP, Backman L, Claesson K et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001: 72: 63.
10. Knoll GA, Mac Donald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
11. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003: 17: 200.
12. Berthoux F, Abramowicz D, Bradley B et al. European Best Practice Guidelines for Renal Transplantation. Section IV: Long-term management of the transplant recipient. IV.9.2. Haematological complications. Leukopenia. Nephrol Dial Transplant 2002: 17 (Suppl 4): 49.
13. Schaub S, Dickenmann M, Cynke E, Bircher A, Steiger J. Prednisone-induced neutropenia after cadaveric kidney transplantation. Nephrol Dial Transplant 2002: 17: 1119.
14. Rolston KV. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: Salient features and comments. Clin Infect Dis 2004: 39: S44.
15. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guidelines. J Clin Oncol 2006: 24: 3187.
16. Tajima A, Aso Y, Kawabe K et al. Colony-stimulating factor for treatment of leukopenia after kidney allografting. Transplant Proc 1991: 23: 1369.
17. Kutsogiannis DJ, Crowther MA, Lazarovits AI. Granulocyte macrophage colony-stimulating factor for the therapy of cytomegalovirus and ganciclovir-induced leukopenia in a renal transplant recipient. Transplantation 1992: 53: 930.
18. Birkeland SA, Elbirk A, Rohr N, Jorgensen KA. Severe neutropenia and its reversal with granulocyte colony stimulating factor. Transplant Proc 1994: 26: 3098.
19. Page B, Morin M, Mamzer M, Thervet E, Legendre C. Use of granulocyte-macrophage colony-stimulating factor in leukopenic renal transplant recipients. Transplant Proc 1994: 26: 283.
20. Squiers EC, Elkhammas EA, Henry ML. Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. Transplant Proc 1995: 27: 3092.
21. Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant 1996: 10: 20.
22. Moghal NE, Milford DV, Darbyshire P. Treatment of neutropenia in a renal transplant recipient with granulocyte colony-stimulating factor. Pediatr Nephrol 1998: 12: 14.
23. Turgeon N, Hovingh GK, Fishman JA et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Tranplant Infect Dis 2000: 2: 15.
24. Schmaldienst S, Bekesi G, Deicher R, Franz M, Hörl WH, Pohanka E. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: A retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation 2000: 69: 527.
25. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: An overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007: 185.